stella
beta
A Study to Evaluate Safety and Efficacy of WSD0922-FU Combo With Osimertinib for NSCLC — Stella
Home
/
Non Small Cell Lung Cancer (NSCLC)
/
View on ClinicalTrials.gov
Recruiting
Back to Non Small Cell Lung Cancer (NSCLC) trials
Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations
(1 site)
China
Shanghai East Hospital, Shanghai